now, adjusted diluted net earnings per common share were $num-one and were up num-two% compared to year-five and we generated $num-three billion of free cash flow in the quarter, bringing our year-to-date total to $num-four billion, which is up num-five% year-over-year.
reported revenue was up num-one% with core revenue up num-two%. our sales were $num-three billion and we delivered num-four% core revenue growth with portfoliowide strength led by diagnostics and life sciences.
we expect to deliver fourth quarter core revenue growth in the low to mid teens range, with high single-digit core revenue growth in our base business and a mid to high single-digit core growth contribution from covid-related revenue tailwind.
our team delivered another outstanding results in our third quarter with over num-one% core revenue growth, nearly num-two% adjusted earnings-per-share growth and strong free cash flow generation.
geographically, high growth markets grew approximately num-one% and developed markets were up nearly num-two%.
in fact, revenue in each of our three largest markets, north america, western europe and china was up approximately num-one% or more in the quarter.
life sciences reported revenue increased num-one% with core revenue up num-two%.
covid-only tests accounted for approximately num-one% of those shipments and our num-txtn-num-two combination tests for covid flu-a and b and rsv represented approximately num-three%.
now for the full year year-six, we now expect to deliver more than num-one% core tailwind and our base business will each contribute more than num-two% to our year-six core revenue growth rate.